Biochemical Pharmacology 1993: Vol 46 Index

41 Pages·1993·7.7 MB·English

Biochemical Pharmacology
SUBJECT INDEX FOR VOLUME 46, 1993
PREPARED BY W. COCKS
BIOCHEMICAL PHARMACOLOGY
EDITORIAL BOARD
Chairman & Regional Editor for the U.K.
Prof. Peter Alexander>
Biochemical Pharmacology U.K. Office, PO Box 11, Cullompton, Devon EX15 1TQ, U.K.
REGIONAL EDITORS:
American Continent European Continent
Prof. Alan C. Sartorelli Prof. Jacques E. Gielen
(Executive Editor) Université de Liége
Yale University School of Medicine Laboratoire de Chimie Medicale
Department of Pharmacology Institut de Pathologie
Sterling Hall of Medicine, 333 Cedar Street B-4000, Sart-Tilman par Liege |
PO Box 208066, New Haven, CT 06520-8066, U.S.A. Belgium
ASSOCIATE EDITORS:
Chemotherapy Endocrinology Genetics
Prof. Yung-Chi Cheng Prof. Priscilla S. Dannies Prof. Daniel W. Nebert
Yale University School of Medicine Yale University School of Medicine Department of Environmental
Department of Pharmacology Department of Pharmacology Health, University of Cincinnati
Sterling Hall of Medicine Sterling Hall of Medicine Medical Center, Kettering
333 Cedar Street, PO Box 208066 333 Cedar Street, PO Box 208066 Laboratory, 3223 Eden Avenue
New Haven, CT 06520-8066, U.S.A. New Haven, CT 06520-8066, U.S.A. Cincinnati, OH 45267-0056, U.S.A
Immunopharmacolog) Neurobiology Neuroscience
Prof. Martin K. Church Dr. Gustave Moonen Prof. Robert H. Roth
Department of Service de Physiologie humaine Yale University School of Medicine
Clinical Pharmacology et de Physiopathologie Department of Pharmacology
Centre Block, Southampton Institut Léon Frédeéricq Sterling Hall of Medicine
General Hospital Place Delcour 333 Cedar Street, PO Box 208066
Southampton SO9 4XY, U.K i7 Bat LI, 4020 Liége, Belgium New Haven, CT 06520-8066, U.S.A
Commentaries Editor
Prof. Harold R. Behrman
Yale University School of Medicine, Departments of Obstetrics/Gynecology and Pharmacology,
Sterling Hall of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, U.S.A
Production Editor (Elsevier Science): Jackie Bannister
Managing Editor: Dr. Kim C. Healy, Yale University School of Medicine, Department of Pharma-
cology, 47 College Street, Suite 227, New Haven, CT 06510-3209, U.S.A.
Publishing and Advertising Offices: Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington,
Oxford OX5 1GB (Oxford 794141), and 660 White Plains Road, Tarrytown, NY 10591-5153. Published
semi-monthly. Annual Institutional Subscription Rates 1994: North, Central and South America,
U.S.$2740, Rest of the World £1778. Associated Personal Subscription Rates are available on request
for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered
customers in the European Community will be charged the appropriate VAT in addition to the price
listed. Prices include postage and insurance and are subject to change without notice. Subscription
enquiries from customers in North America should be sent to: Elsevier Science Inc., 660 White Plains
Road, Tarrytown, NY 10591-5153, U.S.A., and from the remainder of the world to: Elsevier Science
Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, U.K.
Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading
data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions
appearing in the articles and advertisements herein are the sole responsibility of the contributor or
advertiser concerned. Accordingly, the publishers, the editorial board and editors and their respective
employees, officers and agents accept no responsibility or liability whatsoever for the consequences of
any such inaccurate or misleading data, opinion or statement.
Second Class Postage paid at RAHWAY, NJ and additional mailing offices. Postmaster send address
corrections to Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, U.S.A.
Copyright © 1994 Elsevier Science Ltd
EDITORIAL ADVISORY BOARD
American Continent
Jutius Axe_trop—National Institutes of Health, Bethesda, YUTAKA KoBAYASHI Ko-By Associates, 60 Audubon Road,
MD Wellesley, MA
Micuaet R. Boyo—LDDRD, Developmental Therapeutics Wa ter M. LovenBerG Marion Merrell Dow Research
Program, National Cancer Institute, Frederick, MD Institute, Cincinnati, OH
Epwarp Bresnick—Department of Pharmacology and Toxi- P. N. MaGee—Thomas Jefferson University, Cancer Institute,
cology, Dartmouth Medical School, Hanover, NH Philadelphia, PA
D. N. BrinpLeEy—Faculty of Medicine, University of Alberta, G. J. MANNERING—Department of Food Science and
Edmonton, Canada Nutrition, University of Minnesota, St. Paul, MN
MicuHaet J. Brownstein—National Institutes of Health, TaG E. Mansour—Department of Pharmacology, Stanford
Bethesda, MD University Medical Center, Stanford, CA
Jack R. Cooper Yale University School of Medicine, New PauL B. McCay—Oklahoma Medical Research Foundation,
Haven, CT Oklahoma City, OK
James K. Cowarp—College of Pharmacy, University of Hersert Y. MELTZER Case Western Reserve University,
IANM iCchriegeasne,— CAennnt erA rbofro,r MMo lecular and Behavioral Neuro- Cleveland, OH
EstepBaAN Mezey—Johns Hopkins University School of
science, Aidekman Research Center, Newark, NJ Medicine, Baltimore, MD
Joun W. Daty—National Institutes of Health, Bethesda, MD Danie. W. Nesert—Department of Environmental Health,
Erwin G. Erpés—Department of Pharmacology, University University of Cincinnati, Cincinnati, OH
of Illinois, College of Medicine, Chicago, IL Cuarces A. Nicno.—Cannam Enterprises, 1508 Ward Street,
MarPiAa ErecinskA—University of Pennsylvania, Philadelphia, Durham, NC
RayI N W. FuLier Lilly Research Laboratories, Indianapolis, GRaopsserriett E.L . PPaLrakas, JUrn iveBrrsoitwyn oUfn iMvoenrtsirteya,l , PrQouveibdeecn,c e,C anRaI da
Rosert C. GaLto—National Institutes of Health, Bethesda, EuGene Roperts City of Hope Medical Center, Duarte,
MD CA
James R. Gittetre—National Institutes of Health, Bethesda Jerome A. Rotu—State University of New York, Medical
MD Center, Buffalo, NY
Rosert I. GLazer—Georgetown University, Washington, DC CuarcesO . RutLepGe—School of Pharmacy, Purdue Univer-
I. DVva vip GoLtpbMAN—Medical College of Virginia, Richmond, Borsiitsy , TAWeBsAtK OFLFaf—aUyneittvee,r sIiNt y of Colorado School of Medicine,
Tueopore E. GraM—1036 Welsh Drive, Rockville, MD Denver, CO
M. R. HANLEY—School of Medicine, University of California, JOHN F. TALLMAN Neurogen, 35 Northeast Industrial Road,
Davis, CA Branford, CT
G. H. Hitcuincs—Wellcome Research Laboratories, Research Snorri Sv. THORGEIRSSON National Institutes of Health,
Triangle Park, NC Bethesda, MD
Louis J. IGNAaRkRO—UCLA School of Medicine, Department MARTHA VAUGHAN National Institutes of Health, Bethesda,
of Pharmacology, Los Angeles, CA MD
WiiuiaM B. Jakopy—National Institutes of Health, Bethesda, NorMANn Weiner—University of Colorado Health Sciences
MD Center, Denver, CO
Davip G. Jouns—National Institutes of Health, Bethesda, Arno_p D. Wetcu (Chairman)—Frederick Cancer Research
Facility of National Cancer Institute, Frederick, MD
HaAro_D KALANtT—University of Toronto, School of Medicine, Joun R. WiLLiAMSON—University of Pennsylvania, Philadelphia,
Toronto, Ontario, Canada PA
European Continent
F. M. Becpaire—J. F. and C. Heymans Institute of Pharma- G. MittiGAn—Department of Biochemistry, University of
cology, Rijksuniversity, Ghent, Belgium Glasgow, Glasgow, U.K
A. G. H. BLAkeLey—Department of Physiology, The Univer- P. Mo._peus—Department of Toxicology, Karolinska Insti-
sity, Leicester, U tute, 104 01 Stockholm 60, Sweden
K. W. Bock—Institute of Toxicology, Tiibingen University, G. J. Mutper—Department of Toxicology, University of
Germany Leiden, Sylvius Laboratories, P.O. Box 9503, 2300 RA
J. CatpweL__—St. Mary’s Hospital Medical School, London, Leiden, The Netherlands
J.K K. J. NetreER—Department of Pharmacology and Toxicology,
R. A. J. CHatiiss—Department of Pharmacology, University Philipps University, Marburg, Germany
of Leicester, Leicester, U.K H. Nout—Institute of Pharmacology and Toxicology, Uni-
T. A. Connors—Institute of Cancer Research, Sutton, Surrey, versity of Vienna, Vienna, Austria
J.K A. J. Paine—St Bartholomew's Hospital Medical School,
E. De CLercg—Rega Institute for Medical Research, Univer- London, U.K
sity of Leuven, Belgium B. K. Pank—Department of Pharmacology and Therapeutics,
J. Frere—Institute de Chimie, Université de Liége, Liége, University of Liverpool, Liverpool, U.K
Belgium E. URKe to—Guildford Academic Associates, Guildford, Surrey,
T. GopFrainp—Université Catholique de Louvain, Belgium K
R. J. GryGLewski—School of Medicine, Cracow, Poland E. Reiner Yugoslav Academy of Sciences and Arts, 4100
J. HaMon—INSERM U288, Neurobiol Cellulaire et Fonc- Zagreb, Yugoslavia
tionnelle, Faculté de Medecine Pitie-Salpetriere, 91 Blvd de A. G. Renwick—University of Southampton, Faculty of
!' Hopital, F-75634 Paris Cedex 14, France Medicine, Southampton, U.K
J. Hanoune—INSERM U99, H6pital Henri Mondor, Creteil, P. J. Roperts—Department of Pharmacology, University of
France Bristol, Bristol, U.K
J. A. Hickman—Department of Physiological Sciences, M. SANDLER—Bernhard Baron Memorial Research Labora-
University of Manchester, Manchester, U.K tories, Queen Charlotte’s Maternity Hospital, London, U.K
I. JankO—Institute of Pharmacology, Czechoslovak Academy H. Sies—Institut fiir Physiologische Chemie |, Universitat
of Sciences, Czechoslovakia Diisseldorf, Diisseldorf, Germany
P. Jenner—Department of Pharmacology, King’s College. J. Skopa—Institute of Organic Chemistry and Biochemistry,
London SW5 8AF, U.K Czechoslovak Academy of Sciences, Prague, Czechoslo-
H. Kappus—Freie Universitat Berlin, Germany vakia
J. LunpserG—Department of Pharmacology, Karolinska B. Testa—Department of Pharmacy. University of Lausanne.
Institute, Stockholm, Sweden Lausanne, Switzerland
G. P. MANNAERTS—Dienst Farmakoligie, Campus Gasthuis K. Tipton—Department of Biochemistry. University of
berg, Onderwijs en Navorsing, Herestraat, 3000 Leuven, Dublin, Trinity College, Ireland
Belgium V. Uttricn—Fakultat fiir Biologie, Universitat Konstanz,
D. Mansuy—Universite René Descartes, Laboratoire de Konstanz, Germany
Chimie et de Biochemie, Pharmacologiques et Toxicolo- D. C. U’Pricharp—ICI Pharmaceuticals, Research II Dept,
giques, 45 rue des Saints-Péres, 75270 Paris Cédex 05, Mereside Alderley Park, Macclesfield, Cheshire, U.K
France P. WALDMEIER—Ciba-Geigy Limited, CH-4002 Basle, Switzer-
A. E. M. McLean—Department of Clinical Pharmacology, land
University College Hospital Medical School, London, M. B. H. Youpim—Technion-Israel Institute of Technology,
U.K Faculty of Medicine, Department of Pharmacology, Bat
C. J. Meavt Department of Pharmacology, Boehringer Galim, Haifa, Israel
Ingelheim KG, 55216 Ingelheim am Rhein, Germany
Asia and Pacific Rim
YOUNG-Nam CHA—Inha University, Inchon, Korea T. Watast—Tokyo College of Pharmacy, Tokyo, Japan
K. KurivaMaA—Kyoto Prefectural University of Medicine,
Kyoto, Japan
AIMS AND SCOPE
BIOCHEMICAL PHARMACOLOGY is an international journal which publishes research findings in pharmacology
deriving from investigations that employ the disciplines of biochemistry, biophysics, molecular biology, genetics,
structural biology, computer models and/or physiology. Reports of studies with intact animals, organs, cells,
subcellular components, enzymes or other cellular molecules and model systems are acceptable if they define
mechanisms of drug action. Descriptive mathematical models including those involving computer techniques are
also welcome. Experiments involving the use of drugs to elucidate physiological and behavioral mechanisms in
living organisms are also within the scope of the journal. In general, papers which record concentrations of drugs
and metabolites in body fluids will only be accepted if they contribute to an understanding of biochemical and
biophysical mechanisms. The Editors, however, reserve the right to publish any papers of major interest in the
field. Only contributions in English can be considered or published
The journal publishes the following types of communication:
(1) Full-length Papers. These consist of a body of work presenting original findings relating to the question
proposed by the investigators undertaking the research.
(2) Short Communications. These consist of an original body of work of narrower scope but of the same quality
as the above. By definition, these papers are shorter than full-length manuscripts.
(3) Rapid Communications. These promote rapid dissemination of timely and significant observations within
the scope of the journal. Manuscripts must be submitted in English and will be judged as appropriate for
publication as rapid communications on the basis of their immediate importance. They should be written to
emphasize clearly the novel aspects cf the research. These criteria will be applied strictly. In order to speed up
the publication of rapid communications, authors are encouraged to use the special laysheets available from any
of the Regional Editors.
(4) Commentaries are short commissioned review articles (3000-5000 words in length). They are designed tc
be editorial statements on selected topics, and should not be exhaustive reviews. Primarily, Commentaries are
intended to stimulate thought. They can be controversial, and can either focus on areas subject to much activity,
or draw attention to relatively neglected fields in which there are both the opportunity and the need for research
in biochemical pharmacology. Particulariy welcome will be Commentaries in which authors present their personal
view on the state of the subject on which they are reporting, and give their view as to where in the near or distant
future the subject may be moving. Authors are especially encouraged to take issue with popular dogmas. The
Commentary series is edited by Professor Harold R. Behrman.
In order to increase the exchange of information and ideas, the Journal will also publish Comments on a
Commentary, in which selected, highly qualified authorities are invited to offer their own observations on
Commentary articles, which will be published in the same issue of the Journal, and thus provide some alternative
thoughts on important areas of research. For further information see Biochem Pharmacol 31, 2568 (1982).
While the final decision on selection of authors for either Commentaries or Comments on a Commentary will
be made at the discretion of the editor, suggestions from readers will be welcome. These should be addressed
to: Professor H. R. Behrman, Department of Pharmacology, Yale University School of Medicine, 333 Cedar
Street, New Haven, Connecticut 06510.
(5) Meeting Reports. The journal is prepared to publish as preliminary communications short, factual two-page
summaries of selected papers from small meetings or conferences. The meetings should be those where attendance
is by invitation and all papers to be published will be refereed. Organizers who wish to have their meetings
published in this way should contact the appropriate Regional Editor.
Notes for Contributors can be found in all issues and Abbreviations in issues 1 and 7
BIOCHEMICAL PHARMACOLOGY
SUBJECT INDEX FOR VOLUME 46, 1993
&23137 Adenine
effect on arachidonic acid mobiliz- effect on 2',3'-dideoxynucleoside
ation in pancreatic acini 56/7 transport in erythrocytes 725
effect on malaria gamete formation Adenocarcinoma cells CaCo-2
1601 bisphosphonate transport 1591
Acetaminophen effect of NB-598 on lipid secretion
effect on glutathione and PAPS 297
synthesis in hepatocytes 383,1295 Adenosine
hepatic disposition, pharmacokinetic inhibition of transport by propento-
modeling 739 fylline 891
hepatotoxicity Adenosine deaminase
effect of caffeine 493 in thymus and spleen, effect of
effect of cysteine 1295 2'-deoxycoformycin 1071
effect of gomisin A 1081 Adenosine diphosphate-ribosylation
induction of 5-oxoprolinuria in rat effect of pertussis toxin and
953 N-ethylmaleimide 2145
metabolism in mouse, effect of Adenosine-3' ,5'-monophosphate
fluorine substitution 84] activation of lipolysis in white
Acetone adipocytes 5/75
effect on liver esterases 2087 formation in SH-SY5Y cells, effect
regulation of cyt P450 2E1 and of morphine and its metabolites
cyt P450 2Bl in nasal mucosa 1945 1145
Acetyl-L-carnitine forskolin-stimulated accumulation in
effect on neurotoxicity of ammonia MMQ cells, effect of D2 agonists
159 and antagonists 747
Acetylcholinesterase production by adenylyl cyclase from
in erythrocytes, inhibition by goldfish brain 1559
pentachlorophenol 175 Adenosine-3' ,5'-monophosphate-dependent
membrane fluidity 1521 protein kinase
«j-Acid glycoprotein effect on protein kinase activities
effect on quinidine uptake and 439
pharmacodynamics in heart 05 in white adipocytes, fB3-adrenoceptor-
Acivine pseudocyanide induced activation 575
inhibition of collagen-induced Adenosine 3'-phosphate 5'-phosphosul phate
platelet aggregation and adhesion sulphate donar ability 465
1165 synthesis in hepatocytes
Aclacinomycin A effect of acetaminophen 383,1295
efflux in multidrug-resistant cell effect of cysteine 1295
lines 1317 Ca2+-Adenosine triphosphatase
Actinomycin in red blood cell membranes, protect-
resistant Chinese hamster lung cells, ion against free radical damage
effect of epidermal growth factor 525
on P-glycoprotein 1841 ecto-Adenosine triphosphatase
Acyl CoA:cholesterol acyltransferase on human blood cells 1959
in CaCo-2 cells, effect of NB-598 Na+,K*-Adenosine triphosphatase
297 in brain, effect of vitamin E and
Acy1l-CoA oxidase diazepam in stressed rats 194
in hepatoma cells, effect of tetra- endogenous activating factor 125
decylthioacetic acid 1307 in lymphocytes, effect of clofazimine
in liver, effect of fenoprofen 79 and B669 2029
Acyl-CoA synthetase in red blood cell membranes, protect-
in liver, effect of fenoprofen 79 ion against free radical damage
Acyl glucuronides 525
reactivity 1175 Adenosine triphosphate
BIOCHEMICAL PHARMACOLOGY
Adenosine triphosphate Albumin
in hepatocytes preserved in UW human serum
solutions 2093 artemisinin interaction 336
in lung, effect of bleomycin 1819 captopril and penicillamine
in lymphocytes binding 1059
effect of amiodarone 421 carprofen binding 1721, 1733
H905-treated, inhibition of poly- ligand binding using immobilized
(ADP-ribose)polymerase 2139 HPLC phases 1285
Adenosine triphosphate analogues recombinant, binding to 1159
effect on cantharidin and endothall rat and rabbit serum, ligand binding
thioanhydride binding in liver using immobilized HPLC phases
1435 1285
Adenosine triphosphate-citrate lyase Alcohol dehydrogenase
in brown adipose tissue, effect of in hepatocytes, effect of cold
clofibrate 1501 storage 333
S-Adenosylmethionine Aldehyde
role in trypanosome resistance to toxicity in hepatocytes 1621
DL-&-difluoromethylornithine 471 Aldehyde dehydrogenase
S-Adenosylmethionine decarboxylase in blood, inhibition by n-butyrald-
in human and rodent cells, effect of oxime 117
N- (n-butyl )-1,3-diaminopropane in brain, induction and TCDD
717 susceptibility 651
Adenylyl cyclase in erythrocytes, inhibition by
in goldfish brain 1559 methylene blue 2135
in heart, regulation by epidermal leukocytes, inhibition by
growth factor 1239 methylene blue 2135
Adipose tissue liver
brown disulfiram bioactivation 2285,
inhibition of lipogenesis by 2291
clofibrate 1501 induction and TCDD susceptibility
methylamine metabolism by SSAO 651
603 inhibition by methylene blue 2135
white Aldehyde oxidase
effect of clofibrate on lipogene- oxidation of allopurinol and
sis 150] pyrazinamide 975, 2277
correlation of A-kinase and Aldehyde reductase
lipolysis activation 5/75 in placenta, aldophosphamide reduction
histamine lipolytic activity 1369 1043
methylamine metabolism by SSAO Aldophosphamide
603 reduction by aldose reductase and
Adrenaline aldehyde reductase from placenta
in plasma of cocaine abusers 53 1043
stimulated GTPase in platelet Aldose reductase
membranes 2021 human tissues, immunoassay 21
«-Adrenoceptors methylglyoxal metabolism 805
Na*,K*-ATPase regulation following in placenta, aldophosphamide reduct-
blockade of 125 ion 1043
«2-Adrenoceptors Aldrin
in MMQ cells 747 epoxidation in liver microsomes
in platelets, GTPase stimulation 2021 from pregnant and lactating rats
fp-Adrenoceptors 29
Nat ,K*-ATPase reguole ation following Alkaline phosphatase
blockade of 25 role in mineralization of bone and
—B3-Adrenoceptors teeth 1668
in adipoc ytes, A kinase and lipolysis 06-Alkylguanine-DNA alkyltransferase
activat ion 25/ 7 5 in colon tumor xenografts, effect of
Adriamycin Q06-benzylguanine and BCNU 285
induced apoptosis in tumor cells 375 Alkyl N-propargylamines
Adriamycin aglycones inhibition of MAO B 753
effect on selenium-deficient mitoch- Allepurinol
effect on hepatic cyt P450 during
interferon induction 2114
on carbohydrate oxidation by rat liver aldehyde
1539 oxidase 975
letion of oxidation in vivo, effect of
BOF-4272 2277
Ah receptor protection against ischaemia-
jL T lilivveerr effect of 9-hydroxyellipt- reperfusion injury 1749
icine on transformation 1425 + tiazofurine, synergistic action
A-kinase on tumor cells 1903
in white adipocytes, Bp3-adrenoceptor- Alzheimer's disease
induced activation 5/75 aberrant oxidations of 5-HT in
Albumin brain 1637
BIOCHEMICAL PHARMACOLOGY
Alzheimer's disease(contd. ) Anandamide
tacrine metabolism in vitro 13 enzymatic synthesis and degradation
Amanitin 791
specific antibodies, production and Andrographic paniculata
cytoprotective properties 327 antihepatotoxic effects of diterpen-
Amidase oid constituents 182
in neuroblastoma and glioma cells, Angiotensin-converting enzyme inhibitors
anandamine degradation 791 cytotoxicity in cultured rat
Amidoimidazole carboxamide ribonucleo- hepatocytes 2163
side Angiotensin II receptor
reversal of 6-mercaptopurine and in aorta, inhibition by CV-11974 31]
6-methylmercaptopurine ribo- in liver, losartan binding 1653
nucleoside cytotoxicity in Aniline hydroxylase
MOLT F4 lymphoblasts 547 in liver microsomes
Amineptine diabetic rat 621
effect on fatty acid oxidation in effect of pinacolone and acetone
lymphocytes 421 2087
3-Aminobenzamide pregnant and lactating rats 29
effect on bleomycin-induced NAD Anthracyclines
depletion in lung 1819 effect on gastric PGE2 metabolism
effect on 5-fluoropyrimidine cyto- and phospholipase A2 activity 349
toxicity 205 efflux in multidrug-resistant cell
effect on hepatotoxicity of methyl lines 1317
methanesulfonate 1811 induced apoptosis in tumor cells 375
effect on oxidative cell injury 483 topoisomerase II directed, ICRF-187
¥-Aminobutyric acid interaction 389
involvement in cimetidine-induced Anthralin
seizures 2171 hydroxyl radical damage by 1695
&-Aminocephalosporin cephalexin Antibody directed enzyme prodrug therapy
uptake by rabbit small intestine 542 CB1954 activation 797
L-(&-S ,5-S) -a#-Amino-3-chloro-4,5- Antifolate dipeptide
dihydro-5-isoxazoleacetic acid in vivo metabolite stability in mice
inhibition of ¥-glutamyl trans- 2229
peptidase 643 Antifolates
Aminoguanidine determinants of cytotoxicity
catalase inhibition and generation pharmacodynamics of cancer che
of hydrogen peroxide 1139 therapy 2155
o-Amino-3-hydroxy-5-methy1-4-isoxazole- Anti-inflammatory drugs
propionic acid receptors 1877 bisbenzylisoquinoline alkaloid
«-Amino-$-lactam antibiotics effects on nitric oxide production
uptake by rabbit small intestine 542 in macrophages 1887
Aminooxyacetic acid immobilized-albumin HPLC phases in
effect on cimetidine-induced seizures binding 1285
in mice 2171 Antimalarial compounds
D(-)-2-Amino-5-phosphonovalerate effect on oxidative stress and
block in cloned NMDA receptors 1877 antioxidant defenses in mice 1859
Aminopyrine Antioestrogen binding site
accumulation by parietal cells, in liver, human and rat, triphenyl-
effect of Ro 31-8220 583 ethylene binding 1870
Aminopyrine N-demethylase Antioxidant defenses
in liver of pregnant and lactating in mice, effect of antimalarial
rats 29 agents 1859
21-Aminosteroids Antioxidants
inhibition of lipid peroxidation 877 anthrones 1695
Amiodarone atherosclerosis 2119
effect on fatty acid oxidation in dehydroepiandrosterone 1695
lymphocytes 421 dehydrozingerone and isoeugenol 2067
Ammonia in lung, effects of dexamethasone and
neurotoxicity, effect of carnitine hyperoxia 1565
analogues 159 Antipyrine
Amodiaquine metabolism in vivo in rat models of
ferriheme interaction 15/73 liver cirrhosis 983
Amphetamine Aorta
effect on MAO in brain 609 angiotensin II receptor —CV-11974
Amsacrine interaction 31]
resistant HL-60 cells, characteriz- effect of ethacrynic acid on response
ation of topoisomerase II 699 to nitroglycerin 2/79
Amylase isolation of cyclic nucleotide
photodynamic action of SALPC on phosphodiesterase isozymes 833
release of 567 effect of lifibrol on lipid metabolism
Analgesia 1475
cyclic AMP formation 1145 role of c-jun in expression of
Anandamide preproendothelin-1 mRNA in
BIOCHEMICAL PHARMACOLOGY
Aorta(contd. ) 3'-Azido-3'-deoxythymidine(contd. )
in endothelial cells 455 plus ICI D1694, cytotoxicity 1989
trimetoquinol analogues as TXA2 3'-Azido-3'-deoxythymidine 5'-triphos-
receptor antagonists 2051 phate
Aphidicolin HIV-1l reverse transcriptase resist-
potentiation of ara-C induced ant to 2307
apoptesis in HL-60 cells 1909 5-(Aziridin-1l-yl)-2-nitro-4-nitroso-
Apolipoprotein B benzamide
secretion ff rom Caco-2 cells, effect synthesis and properties 797
of NB-598 297
Apoptosis
HL-60 cells B24
ara-C induced, effect of effect on histamine lipolvtic activity
aphidicolin 1909 1369
3-deazaadenosine induced 1893 B669
tumor cells,-.anthracycline induced phospholipase-activating and
375 immunosuppressive properties 2029
1-B-D-Arabdinofuranosy]-E-5-(2-bromo- Bacillus Calmette-Guerin/lipopolysacc-
vinyl )uracil haride
5'-ether prodrugs, metabolism in rats induced hepatitis, effect of
2201 bisbenzylisoquinoline alkaloids
1-B-D-Arabinofuranosylcytosine 1861
induced aopotosis in HL-60 cells, Baclofen
effect of aphidicolin 1909 effect on cimetidine-induced
Arachidonic acid seizures in mice 2171
as a retrograde messenger 7/77 Basophilic leukemic cells
mobilization in pancrearic acini, quercetin induction of mast cell
effect of SALPC 567 protease II 2315
Arginine Benf luorex
in plasma, in hypercholesterolaemia effect on hepatic carbohydrate
2097 metabolism 1539
Aroclor 1254 Benzamide
effect on alkoxyresorufin O-dealkyl- effect on oxidative cell injury 483
ation in liver 933 1,2-Benzanthracene
Artemisinin effect on cytochrome P450 and UDPGT
alkylation of human albumin 336 in HepG2 cells 629
Artery Benzene
lipoprotein oxidation and gene effect on membrane fluidity, bile
expression 2119 flow and K* trandport in liver
Arylmethanes 1207
heterocycle-containing, induction of modulation of toxicity by protein A
rat lung drug-metabolizing 517
enzymes 683 Benzodiazepine receptors
2-Aryl-propionic acid non-steroidal in lymphocytes and glial cells,
anti-inflammatory drugs modulation by interleukin-]1 and
immobilized-albumin HPLC phases in phorbol myristate acetate 821
binding studies 1285 in phagocytic cells 55]
Ascorbic acid Benzodiazepines
effect on po lychlorinated biphenyl binding to rat and rabbit serum
induct ion of cyt P450 mRNAs in albumin, HPLC stationary phases
liver 186 1285
protection against ischaemia-reper- binding to recombinant human serum
fusion injury 1749 albumin 1159
uptake by hepatocytes, effect of stimulation of plasminogen-
diquat 1bw3w3s3e activator synthesis 6]
Aspirin 7,8-Benzoflavone
alleviation cyclosporin A nephro- effect on alkoxyresorufin metabolism
of
toxicit 2104 in liver 933
A eS ‘
Atherosclerosis Benzo(a)pyrene
]l ipid metabolism metabolism in cryopreserved hepato-
cytes 111
5-Benzylbarbituric acid derivatives
lipoprotein pharmacologic inhibition of uridine phosphorylase
interventior 1273
Atropine 06-Benzylguanine
effect on effect on sensitivity of colon
Autonomic tumor xenografts to BCNU 285
effect on gastric 1-Benzylimidazole
Azaanthracene-9,10-diones effect on metabolism of 5-methyl-
cytotoxicity in HL-60 cells 265 N,N-diethylthiocarbamate in
3'-Azido-3'-deoxythymidine liver 2285, 2291
permeation and metabolism in human 5-Benzyloxybenzylbarbituric acid
cells 273 inhibition of uridine phosphorylase
BIOCHEMICAL PHARMACOLOGY
5-Benzyloxybenzylbarbituric acid(contd. ) Blood coagulation factor
1849 effect of vitamin K forms 433
5-Benzyloxybenzyluracil BOF-4272
inhibition of uridine phosphorylase effect on oxidation of allopurinol
1849 and pyrazinamide in vivo 2277
Benzyloxyresorufin O-dealkylase Bone
in HepG2 cells, induction 629 mineralization, role of alkaline
in liver, cyt P450 isozyme specific- phosphatase 1668
ity 933 effect of vitamin K2 on prostaglandin
6-Benzy1-2-thiouracil metabolism 1355
inhibition of uridine phosphorylase Bone marrow cells
1849 effect of AZT + ICI D1694 1989
Berberine dideoxynucleoside permeation and
effect on BCG/LPS-induced hepatitis metabolism 273
and TNF production 1861 modulation of benzene toxicity by
DNA interaction, thermodynamics 1665 protein A 51/7
Bezafibrate effect of swainsonine analogues on
effect on fatty acid chain elongation proliferation 1459
and desaturation 1/791 Bradykinin receptor
BIBW-22 in uterus, T-kinin binding 16-7
effect on chloroquine resistance in Brain
Plasmodium falciparum 1421 ammonia toxicity, effect of
Bicucul line carnitine analogs 159
effect on cimetidine-induced seizures anandamide amidase in 791
in mice 2171 Nat+,K+-ATPase endogenous regulating
Bile acids factor 125
excretion in diabetic rats, effect calcium uptake, effect of domoate,
of vanadate 2269 glutamate and glucose 131
effect of hepatic glutathione on cyclosporin A permeability 1096
cholesterol 7ax-hydroxylase mRNA dehydrozingerone, isoeugenol and
555 lipid peroxidation 2067
transport by human hepatocytes, enzyme induction by TCDD in
effects of cyclosporin A 813 susceptible and resistant rat
uptake and excretion, effect of strains 651
e«- and B-naphthylisothiocyanate effect of ethanol on catalase
2061 during development 1873
Bile flow goldfish
in diabetic rats, effect of vanadate adenylyl cyclase in 1559
2269 kainate binding protein 539
effect of «- and B-naphthylisothio- hydrolysis and binding of a toxic
cyanate 2061 soman isomer 1413
effect of organic salvents 1207 5-HT1p binding sites in caudate
Biliary cirrhosis nucleus 535
antipyrine metabolism in vivo 983 effect of imipramine on phosphatidyl-
Biabenzylisoquinoline alkaloids ethanolamine methylation 449
effect on BCG/LPS-induced hepatitis effect of d-methamphetamine on MAO
and TNF production 1861 609
effect on nitric oxide production in opiate receptors and UV photoaffinity
macrophages 1887 labeling 1119
(1-(2',5'-Bis-O-(tert-butyldimethylsilyl) toluene-induced oxidative stress 103
-B-D-ribofuranosyl )-3-N-methyl- effect of vitamin E and diazepam on
thymine) -3'-spiro-5"'-(4"-amino- metabolism in stressed rats 194
1"',2"-oxathiole-2",2"-dioxide Breast cancer cells
metabolism and pharmacokinetics 69 MDA-486, effect of L86-8275 on
1,3-Bis(2-chloroethyl)-1l-nitrosourea p34cdce2 phosphorylation 1831
colon tumor sensitivity, effect of T47-D, spermidine/spermine N'-
Q°-benzylguanine 285 acetyltransferase induction by
Bis(3,5-dibromosalicyl)fumarate methylglyoxal bis(guanylhydrazone)
modified hemoglobin, stability to 969
oxidative damage 2299 BRL 37344
Bisphosphonate lipolytic action in white adipocytes
transport in CaCo-2 cells 1591 575
Bladder N-(2-p-Bromocinnamylamino)ethyl)-5-
diflunisal covalent adducts 1175 isoquinolinesul phonamide
Bladder cancer cells MGH-U1 inhibition of BRL 37344 activated
effect of AZT + ICI D1694 1989 lipolysis 575
Bleomycin 2-Bromoisovalerylurea
effect on nucleotides in lung 1819 stereoselectivity of human gluta-
Blood thione S-transferase isoenzymes
xenobiotic metabolizing esterases in 1775
1125 S-(p-Bromophenyl)-L-cysteine sulphoxide
Blood-brain barrier p-bromothiophenol and S(p-bromo-
cyclosporin A transport 1096 phenyl )-L-cysteine formation 1113
6 BIOCHEMICAL PHARMACOLOGY
Brown adipose tissue Calcium(contd. )
inhibition of lipogenesis by in tumor cells, effect of Lonidamine
clofibrate 1501 330
methylamine metabolism by SSAO 603 uptake by brain, effect of domoate,
Brush border membrane glutamate and glucose 131
intestine, cephalexin and cefixime Calcium channels
uptake 542 Mg-nucleotide reguiation of 1103
Butantrone Calcium channel antagonists
hydroxyl radical damage by 1695 back-phosphorylation with protein
Buthionine sulphoximine kinase C 677
effect on glutathione and PAPS effect on calcium overload in
synthesis in hepatocytes 383 hepatocytes 1937
Butylated hydroxytoluene Calphostin C
protection of ion transport ATPases inhibition of thrombin-induced
in red blood cell membranes 525 expression of preproendothelin-|1
2-(4-t-Butylcyclohexyl )-3-hydroxy-1,4- mRNA 455
naphthoquinone Camptothecin
hydroxylation by cyt P450 2C9 in effect on leukemia cells resistant
human liver 1183 to doxorubicin 851
N-(n-Butyl)-1,3-diaminopropane Cancer chemotherapy
effect on polyamine metabolism and by antifolates, pharmacodynamics
cell growth 717 2155
t-Butylhydroperoxide Cannabinoid receptor agonist
hepatotoxicity, effect of Andro- anandamide 791
graphis paniculata diterpenes 182 Cannabinoids
oxidative injury in hepatocytes and metabolism by cyt P450 in liver 405
fibroblasts, effect of 3-amino- Captopril
benzamide and benzamide 483 albumin binding 1059
§-tert-Butyl methotrexate cytotoxicity in rat hepatocytes 2163
transport in CEM/MTX leukemic Carbachol
lymphoblasts 871 stimulated gastric acid secretion,
n-Butyraldoxime effect of Ro 31-8220 583
activation by cyt P450 in liver 11? Carbamylcholine
effect on gastric PAF 37
Carbohydrate
CaCo 2 cells metabolism in liver, effect of
apical excretion of biotransformation benfluorex 1539
products 1393 Carbon tetrachloride
bisphosphonate transport 1591 hepatotoxicity
effect of NB-598 on lipid secretion effect of Andrographis paniculata
297 diterpenes 182
Caffeine protection by dehydroepiandro-
interaction with acetaminophen 493 sterone 1689
effect on malaria gamete formation protection by taurine 589
1601 role of calcium 2039
Caffeine analogues induced liver cirrhosis, antipyrine
stimulation of calcium release in metabolism in vivo 983
pheochromocytoma cells 1825 effect on membrane fluidity, bile
Calcineurin flow and Kt transport in liver
cyclosporin binding 1207
Calcium Carboplatin
block in cloned NMDA receptors 1877 DNA adduct formation, effect of
in hepatocy tes, effect of cocaine temperature 1229
1967 enhanced activation by oxygen free
leukotriene B4 induced mobilization radicals 1377
in neutrophils 139 5-Carboxyamidotryptamine
effect on malaria gamete formation inhibition of 5-HT binding in sheep
1601 caudate nucleus 535
in osteoblastic cells, effect of Carboxylesterase
phosphatidylinositol-specific elevation of cellular cysteine 1131
phospholipase C 1668 in liver, enhancement by soman 2083
overload in hepatocytes, effect of xenobiotic metabolizing in human
calci um antagonists 1937 liver and plasma 1125
in platelets, effect of genistein Cardiomyocytes
395 effect of sodium tanshinone IIA
release pheochromocytoma cells, sulfonate 2327
effec f caffeine analogues 1825 transforming growth factor B-1
role in carbon tetrachloride cyto- receptor 511
toxicity 2039 Cardiovascular disease
role in DNA synthesis induction in lipoprotein 1675, 2119
hepatocytes by ciprofibrate 2219 Carnitine
role in polyamine acetylation in C-methylated analogues, effect on
breast cancer cells 969 mitochondrial fatty acid